锦波生物
(832982)
| 流通市值：220.23亿 | | | 总市值：424.77亿 |
| 流通股本：4589.11万 | | | 总股本：8851.18万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 366,465,963.91 | 1,442,831,399.69 | 988,391,498.12 | 602,879,079.52 |
| 营业收入 | 366,465,963.91 | 1,442,831,399.69 | 988,391,498.12 | 602,879,079.52 |
| 二、营业总成本 | 170,803,059.27 | 593,759,725.34 | 387,638,655.67 | 247,807,728.65 |
| 营业成本 | 36,235,023.96 | 115,199,689.85 | 75,436,159.62 | 50,771,004.41 |
| 税金及附加 | 4,747,580.76 | 11,100,457.51 | 6,804,928.54 | 4,034,454.9 |
| 销售费用 | 78,181,602.67 | 258,541,974.84 | 171,759,062.02 | 107,759,972.91 |
| 管理费用 | 30,267,601.7 | 127,369,723.95 | 83,189,976.3 | 55,749,389.85 |
| 研发费用 | 19,030,382.1 | 71,213,218.83 | 43,370,119.62 | 24,696,888.94 |
| 财务费用 | 2,340,868.08 | 10,334,660.36 | 7,078,409.57 | 4,796,017.64 |
| 其中:利息费用 | 2,255,310.11 | 10,490,652.66 | 7,587,269.45 | 5,112,163.96 |
| 其中:利息收入 | 211,678.96 | 1,034,367.19 | 772,239.4 | 489,699.25 |
| 加:投资收益 | 1,024,969.32 | 1,277,383.57 | 976,164.4 | 648,698.64 |
| 资产减值损失(新) | -2,102,097.17 | -13,872,526.14 | -3,472,105.73 | -2,181,510.26 |
| 信用减值损失(新) | 1,435,755.74 | -4,131,325.07 | -2,078,305.89 | -263,816.41 |
| 其他收益 | 2,991,854.02 | 21,965,364.57 | 14,150,800.84 | 8,311,756.87 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 199,013,386.55 | 854,310,571.28 | 610,329,396.07 | 361,586,479.71 |
| 加:营业外收入 | 322.99 | 6,049,105.43 | 46,175.86 | 27,288.98 |
| 减:营业外支出 | 1,791,339.48 | 2,908,927.02 | 2,168,546.66 | 74,732.55 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 197,222,370.06 | 857,450,749.69 | 608,207,025.27 | 361,539,036.14 |
| 减:所得税费用 | 29,041,423.68 | 126,276,216.02 | 88,281,772.38 | 51,998,049.63 |
| 六、净利润 | 168,180,946.38 | 731,174,533.67 | 519,925,252.89 | 309,540,986.51 |
| 持续经营净利润 | 168,180,946.38 | 731,174,533.67 | 519,925,252.89 | 309,540,986.51 |
| 归属于母公司股东的净利润 | 168,530,398.04 | 732,301,620.38 | 519,948,617.6 | 309,564,103.76 |
| 少数股东损益 | -349,451.66 | -1,127,086.71 | -23,364.71 | -23,117.25 |
| (一)基本每股收益 | 1.9 | 8.27 | 5.87 | 3.5 |
| (二)稀释每股收益 | 1.9 | 8.27 | 5.87 | 3.5 |
| 九、综合收益总额 | 168,180,946.38 | 731,174,533.67 | 519,925,252.89 | 309,540,986.51 |
| 归属于母公司股东的综合收益总额 | 168,530,398.04 | 732,301,620.38 | 519,948,617.6 | 309,564,103.76 |
| 归属于少数股东的综合收益总额 | -349,451.66 | -1,127,086.71 | -23,364.71 | -23,117.25 |
| 公告日期 | 2025-04-22 | 2025-04-21 | 2024-10-21 | 2024-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |